Hyperphosphatemia Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of Hyperphosphatemia Treatment Market
The hyperphosphatemia treatment market size was valued at USD 1.23 billion in 2022, and the market is now projected to grow from 1.31 billion in 2023 to USD 2.28 billion by 2030, exhibiting a CAGR of 8.2% during the forecast period of 2023-2030.
The market grew slowly during COVID-19 as a result of disruptions in the supply chain and a rise in the mortality rate. The COVID-19 outbreak's abrupt start in 2020 caused the market for treatments for hyperphosphatemia to stall down. This was caused by a significant decrease in the number of patients receiving hemodialysis and with chronic kidney disease going to the doctor for routine examinations, which left fewer people having their hyperphosphatemia tested. Government has put restrictions on social gatherings, events and moving out from home which make the people homesick. Numerous companies are encountering hurdles due to covid pandemic as the outbreak situation has curtailed production and supply chain which has hindered the market switched to treating covid patients as priority over the other procedures which led the hyperphosphatemia treatment market growth. Additionally, manpower shortages affected manufacturing plants and slowed production due to movement restrictions and lockdowns in several regions. Stopped providing on-site maintenance and installations market growth sputtered amid the pandemic.
Putting more of an emphasis on R&D by industry participants to develop novel therapeutics and drive hyperphosphatemia treatment market growth. Globally, the prevalence of hyperphosphatemia is rising at an alarming rate. This has increased the need for innovative medications with fresh modes of action. Players in the market are putting more effort into introducing new, more efficient items in an effort to grow their clientele. Adrelyx, for example, discovered and created XPHOZAH (tenapanor), a non-phosphate binder. Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) minimally absorbed inhibitor of the gastrointestinal tract. The drug's mode of action is non-phosphate-binding. Research has demonstrated that Tenapanor significantly reduced the number of pills required to maintain serum phosphorus control (up to 80% less than with phosphate binders).
Patients with CKD and dialysis patients are more likely to have hyperphosphatemia. Consequently, the prevalence of hyperphosphatemia has been rising along with the burden of these disorders. Creation of novel therapies for hyperphosphatemia will promote hyperphosphatemia treatment market growth during forecast period. Controlling the phosphate levels in dialysis patients is crucial. Phosphate levels remain poorly regulated despite advancements in dialysis technology. Furthermore, hyperphosphatemia in dialysis patients may be caused by variations in the dialytic elimination of phosphate, inexplicable enteral phosphate absorption by meal or vitamin D intake, and binder efficacy. Thus, researchers are concentrating on creating novel hyperphosphatemia medicines and revising treatment guidelines in order to improve the effectiveness of the hyperphosphatemia treatment procedures in dialysis patients.
Comprehensive Analysis of Hyperphosphatemia Treatment Market
The hyperphosphatemia treatment market and healthcare industry is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the pharmacy benefit management industry. These segmentations are methodically segregated by drug class and by distribution channel. The drug class segmentations include Sevelamer, Calcium-based Phosphate Binders, Lanthanum Carbonate, Iron-based Phosphate Binders, Others, and Non-Phosphate Binders, By Distribution Channel segmentations include Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
The North America region lead the hyperphosphatemia treatment market by benefitting a market size of USD 0.53 billion in 2022 due to robust healthcare infrastructure and Numerous CKD patients in the area contribute to the significant revenue the regional market generates.
The top players in the market play a crucial role in the healthcare industry assuring industrial prospectus growth and setting market standards. These players include Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Lupin (India), Astellas Pharma Inc. (Japan), Akebia Therapeutics, Inc. (U.S.), CSL (Australia), Ardelyx (U.S.), Unicycive (U.S.) these market players provide a level-playing competitive landscape.
In Auust 2023, Astellas Pharma Inc. and DivcoWest, a DivCore Capital Company, worked together. The partnership intended to open Astellas' new life science center on Morgan Avenue in Cambridge.
Segmentation Table
ATTRIBUTE DETAILS
Study Period 2019-2030
Base Year 2022
Estimated Year 2023
Forecast Period 2023-2030
Historical Period 2019-2021
Growth Rate CAGR of 8.2% from 2023-2030
Unit Value (USD billion)
Segmentation By Drug Class
Sevelamer
Calcium-based Phosphate Binders
Lanthanum Carbonate
Iron-based Phosphate Binders
Others
Non-Phosphate Binders
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America (By Drug Class, By Distribution Channel, and By Country)
U.S.
Canada
Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
U.K.
Germany
France
Spain
Italy
Scandinavia
Rest of Europe
Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
Japan
China
Australia
India
South East Asia
Rest of Asia Pacific
Latin America (By Drug Class, By Distribution Channel, and By Country/Sub-region)
Brazil
Mexico
Rest of Latin America
Middle East & Africa (By Drug Class, By Distribution Channel, and By Country/Sub-region)
GCC
South Africa
Rest of the Middle East & Africa
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Hyperphosphatemia, By Key Countries/ Regions, 2022
- 4.2. Pipeline Analysis, By Key Players
- 4.3. Global Revenues Generated by Major Branded Drugs
- 4.4. New Drug Class Launches, By Key Players
- 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.6. Impact of COVID-19 on the Market
- 5. Global Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 5.1. Market Analysis, Insights and Forecast – By Drug Type
- 5.1.1. Sevelamer
- 5.1.2. Calcium-based Phosphate Binders
- 5.1.3. Lanthanum Carbonate
- 5.1.4. Iron-based Phosphate Binders
- 5.1.5. Others
- 5.1.6. Non-Phosphate Binders
- 5.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.2.1. Hospital Pharmacies
- 5.2.2. Retail Pharmacies
- 5.2.3. Online Pharmacies
- 5.3. Market Analysis, Insights and Forecast – By Region
- 5.3.1. North America
- 5.3.2. Europe
- 5.3.3. Asia Pacific
- 5.3.4. Latin America
- 5.3.5. Middle East Africa
- 6. North America Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 6.1. Market Analysis, Insights and Forecast – By Drug Type
- 6.1.1. Sevelamer
- 6.1.2. Calcium-based Phosphate Binders
- 6.1.3. Lanthanum Carbonate
- 6.1.4. Iron-based Phosphate Binders
- 6.1.5. Others
- 6.1.6. Non-Phosphate Binders
- 6.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.2.1. Hospital Pharmacies
- 6.2.2. Retail Pharmacies
- 6.2.3. Online Pharmacies
- 6.3. Market Analysis, Insights and Forecast – By Country
- 6.3.1. U.S.
- 6.3.2. Canada
- 7. Europe Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 7.1. Market Analysis, Insights and Forecast – By Drug Type
- 7.1.1. Sevelamer
- 7.1.2. Calcium-based Phosphate Binders
- 7.1.3. Lanthanum Carbonate
- 7.1.4. Iron-based Phosphate Binders
- 7.1.5. Others
- 7.1.6. Non-Phosphate Binders
- 7.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.2.1. Hospital Pharmacies
- 7.2.2. Retail Pharmacies
- 7.2.3. Online Pharmacies
- 7.3. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.3.1. U.K.
- 7.3.2. Germany
- 7.3.3. France
- 7.3.4. Spain
- 7.3.5. Italy
- 7.3.6. Scandanavia
- 7.3.7. Rest of Europe
- 8. Asia Pacific Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 8.1. Market Analysis, Insights and Forecast – By Drug Type
- 8.1.1. Sevelamer
- 8.1.2. Calcium-based Phosphate Binders
- 8.1.3. Lanthanum Carbonate
- 8.1.4. Iron-based Phosphate Binders
- 8.1.5. Others
- 8.1.6. Non-Phosphate Binders
- 8.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.2.1. Hospital Pharmacies
- 8.2.2. Retail Pharmacies
- 8.2.3. Online Pharmacies
- 8.3. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.3.1. Japan
- 8.3.2. China
- 8.3.3. Australia
- 8.3.4. India
- 8.3.5. South East Asia
- 8.3.6. Rest of Asia Pacific
- 9. Latin Smerica Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 9.1. Market Analysis, Insights and Forecast – By Drug Type
- 9.1.1. Sevelamer
- 9.1.2. Calcium-based Phosphate Binders
- 9.1.3. Lanthanum Carbonate
- 9.1.4. Iron-based Phosphate Binders
- 9.1.5. Others
- 9.1.6. Non-Phosphate Binders
- 9.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.2.1. Hospital Pharmacies
- 9.2.2. Retail Pharmacies
- 9.2.3. Online Pharmacies
- 9.3. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.3.1. Brazil
- 9.3.2. Mexico
- 9.3.3. Rest of Latin America
- 10. Middle East & Africa Hyperphosphatemia Treatment Market Analysis, Insights and Forecast, 2019-2030
- 10.1. Market Analysis, Insights and Forecast – By Drug Type
- 10.1.1. Sevelamer
- 10.1.2. Calcium-based Phosphate Binders
- 10.1.3. Lanthanum Carbonate
- 10.1.4. Iron-based Phosphate Binders
- 10.1.5. Others
- 10.1.6. Non-Phosphate Binders
- 10.2. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.2.1. Hospital Pharmacies
- 10.2.2. Retail Pharmacies
- 10.2.3. Online Pharmacies
- 10.3. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.3.1. South Africa
- 10.3.2. GCC
- 10.3.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2022)
- 11.2. Company Profiles
- 11.2.1. Sanofi
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. Takeda Pharmaceutical Company Limited
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. Lupin
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Astellas Pharma Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Akebia Therapeutics, Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. CSL
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Ardelyx
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. Unicycive
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook